Whilst insulin therapy remains the mainstay treatment for type 1 diabetes mellitus (T1DM), the European Society of Cardiology recommends SGLT2is as a first‐line drug therapy for ASCVD patients diagnosed with T2DM.5 This evidence concerns the gene INS and type 1 diabetes mellitus.